EP-1213: The first experience of stereotactic radiotherapy in patients with pancreatic cancer  by Znatkova, Y. et al.
S656                                                                                                                                         3rd ESTRO Forum 2015 
 
to the very slow progress in evaluating novel neoadjuvant 
strategies in rectal cancer. 
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Purpose/Objective: This study was planned to clarify the 
optimal treatment for squamous cell carcinoma of the 
rectum, an histological entity extremely rare. 
Materials and Methods: The analysis includes 8 patients 
treated in the Radiotherapy Department of 'Università 
Sapienza di Roma' and 'Università Cattolica del Sacro Cuore di 
Roma'. Patients, retrospectively reviewed, were affected by 
histologically proven rectal squamous cell carcinoma, without 
any distant metastases, any anal canal extension and any 
fistulous tract. Due to the histological nature of the tumour, 
patients were staged according to AJCC TNM Staging System 
2010 for anal squamous cell carcinoma: 3 patients were 
clinically staged as IIIA (perirectal lymph nodes), 3 patients 
as IIIB (unilateral iliac and/or inguinal lymph node) and 2 
patients as II. All patients received definitive concomitant 
radiochemotherapy (RT-CHT). Radiation therapy was 
delivered with a 3D-conformational multiple field technique 
to a dose ranging from 45 to 76.5 Gy, with 6 - 15 MV energy 
photons. Target volume included primary tumor, mesorectal 
and posterior pelvic subsite, and regional node (internal and 
external iliac, presacral, obturator, inguinal lymph nodes). 
Chemotherapy consisted of an antimetabolite drug (5-
Fluorouracile or Raltitrexed) in association with mitomycin C 
or oxaliplatin.  
Results: All patients completed programmed RT-CHT 
treatment. Severe acute toxicity by RTOG scale was not 
recorded. All patients developed mild (G1) to moderate (G2) 
gastrointestinal toxicity, as well as a perineal skin reaction ≤ 
G2. Six months after the end of treatment, 7 patients (87.5 
%) showed a tumour regression, both complete (n = 6) and 
partial (n = 1). One patients presented persistent disease and 
underwent salvage surgery.  With a mean follow-up of 41.75 
months, 7 patients are still a disease free survivors and 
preserving anus and rectum. Only 1 patient developed local 
recurrence at 6 months and he died 14 months after 
abdomino-perineal resection. 
Conclusions: Primary RT-CHT, with a curative intent, should 
be considered the treatment modality of choice for squamous 
carcinoma of the rectum. As for the anal carcinoma, surgery 
should have a limited place in the initial management of this 
disease. In the squamous cell carcinoma of the rectum, 
surgery has to be used only with salvage intent. High dose 
radiation therapy and concomitant chemotherapy regime as 
for anal canal tumor could guarantee a complete control of 
disease. 
   
 
 
 
 
EP-1213   
The first experience of stereotactic radiotherapy in 
patients with pancreatic cancer 
Y. Znatkova1, S.V. Medvedev1, D.S. Romanov1, S.I. Tkachev1 
1Russian cancer Research Center NN Blokhin, Radiation 
Oncology, Moscow, Russian Federation  
 
Purpose/Objective: The frequency of cases of resectable 
pancreatic cancer is less than 20%. Locally advanced diseases 
about 30% of all cases, and in 50% of cases the disease has 
metastases.The average life expectancy in resected patients 
only after surgical treatmentis an average of 12 – 13 months. 
Low life expectancy, poor treatment efficacy, duration and 
tolerability of heavy teletherapy course force radiologists to 
look for other options to help patients with pancreatic 
cancer. SBRT(Stereotactic Body Radiation Therapy) is a new 
method of treatment for these patients. In RCRC named after 
N.N. Blokhin has developed a methodology of SBRT using 
intensity modulated arches, with 7.5 Gy per fraction, 5 times 
a week, up to 37.5 Gy under the control of the imaging 
(IGRT). The aim of this study is to evaluate the efficacy and 
safety of stereotactic radiotherapy for pancreatic cancer in 
patients who have been denied an alternative treatments. 
Materials and Methods: From 2010 to 2013 SBRT with 
intensity modulated arches has been performed in 8 patients 
with pancreatic cancer. In 7 of 8 patients tumor was 
localized in the head of the pancreas, and 1 patient had loss 
of body and tail of the pancreas. Indifferent periods (1 - 3 
years) 4 patients who had radical surgery gained local 
recurrence of the disease. In 4 patients after palliative 
surgery and chemotherapy continued growth and further 
metastasis process was observed. All 8 patients had a course 
of stereotactic body radiotherapy (SBRT) under the control of 
the visualization (IGRT) using VMAT technique (RapidArc) on 
electron accelerator Varian Clinac 2300iX, multileaf 
collimator Milenium 120 and dynamic wedge filters, 6 MeV 
photon energy. Verification of the plan was performed using 
Cone-Beam CT and X-ray images in kilovolt beam. The dose 
was 7,5 Gy perfraction, up to 37,5 Gy. 
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Results: 5 of 8 patients are alive. Median follow-up was 8.5 
months. Two patients (25%) achieved tumor progression. In 
one patient (12%) complete response was observed, in two 
patients (25%) –stable disease, in three (38%) - partial 
response. Local control is 75%. In all was mild or moderate 
toxicity, which was fully treated by symptomatic therapy. 3 
of 8 patients died from further disease progression and 
metastatic process. 
Conclusions: The proposed method of fractionation in 
stereotactic body radiotherapy is effective, has medium 
toxicity and can be used in patients with inoperable 
pancreatic cancer. 
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Purpose/Objective: Patients with esophageal cancer not 
suitable for surgery, due to irresectability of the tumour or 
inoperability of the patient, can be treated with definitive 
chemoradiotherapy (dCRT) with curative intent. The purpose 
of this study is to evaluate the clinical outcomes of dCRT 
using Carboplatin and Paclitaxel. 
Materials and Methods: A retrospective cohort study was 
conducted in 2 collaborating institutes. Included patients 
were treated between January 2009 and December 2013, 
fulfilling the following criteria: primary squamous cell- or 
adenocarcinoma of the esophagus without signs of distant 
metastasis and treated with dCRT. Treatment consisted of 
external beam radiotherapy (28 fractions of 1.8 Gy) and 6 
weekly courses of Carboplatin (AUC 2) and Paclitaxel (50 
mg/m2). Survival, local and distant disease progression was 
recorded. Acute and late toxicity was scored according to the 
CTCAE v 4.0. For dysphagia scoring according to Knyrim was 
used. 
Results: Sixty-six patients were included, of whom 91% 
completed the radiotherapy and 82% received ≥ 80% of 
prescribed chemotherapy dose. Patient characteristics are 
shown in table 1. Median FU of patients alive was 26.6 
months. Median OS was 13.1 months (figure 1). Median PFS 
was 8.7 months. Eighteen patients (27%) had local 
progression and in total 27 patients (41%) developed distant 
metastasis. Two year OS, PFS and cumulative incidence of 
local progression were 30%, 23% and 26% respectively. In 
univariate analysis, tube feeding before start of dCRT and 
high dysphagia score were significant prognostic factors for 
worse OS. None of these factors were significant in 
multivariate analysis. Acute toxicity grade ≥ 3 was scored in 
47% of all patients. The majority was haematological toxicity 
grade 3-4, due to low blood counts. Only 3% had a severe 
infectious adverse event. 18% of patients had acute 
gastrointestinal toxicity. Late adverse events grade ≥ 3 were 
seen in 20% of all patients, most events were esophageal 
stenoses. There were two treatment related deaths. Of the 
46 patients with available data on dysphagia score at 3 
months, 70% had a better dysphagia score than before dCRT. 
Of 30 patients with tube feeding during treatment, only 4 
patients still required tube feeding 3 months after dCRT. 
  
 
